Vaishali Kumar, MBBS, Sarcoma Oncology Research Center, Santa Monica, CA, discusses findings from an analysis of CCNG1 expression in 137 patients across various cancer types treated with DRG-101, a tumor-targeted retrovector. All tumors exhibited enhanced CCNG1 expression, with varying levels across patients. Notably, patients with sustained remission from metastatic pancreatic cancer and breast cancer showed specific CCNG1 expression levels. DRG-101 additionally has potential in combination therapy for advanced pancreatic cancer, sarcoma, and breast carcinoma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.